<DOC>
	<DOCNO>NCT01583244</DOCNO>
	<brief_summary>The purpose post-marketing surveillance investigate confirm type incidence newly identify adverse event factor affect safety efficacy Orencia® regulatory authority manage marketing approval properly .</brief_summary>
	<brief_title>Korean Post-marketing Surveillance Orencia®</brief_title>
	<detailed_description>Time Perspective : Prospective / Retrospective ( On-treatment )</detailed_description>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Abatacept</mesh_term>
	<criteria>For information regard BMS clinical trial participation , please visit www.BMSStudyConnect.com Patients must diagnose : Adult Rheumatoid arthritis ( RA ) : adult patient moderatetosevere active RA Or Juvenile idiopathic RA : juvenile patient age 6 year old moderatetosevere active RA Children age &lt; 6 year Pregnant lactating woman Patients participate another study Patients know hypersensitive active component surveillance drug component surveillance drug Patients positive tuberculosis screen test treat standard therapy participate study Patients positive hepatitis virus test Patients give live vaccine concurrently surveillance drug expect give live vaccine within 3 month discontinuation surveillance drug</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>